Included as part of the PRECAUTIONS section.

Cell Death

Mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2 mg/mL or use for longer than 2 minutes may lead to unintended corneal and/or scleral damage including thinning or perforation. Direct contact with the corneal endothelium will result in cell death.

Hypotony

The use of mitomycin has been associated with an increased instance of post-operative hypotony.

Cataract Formation

Use in phakic patients has been correlated to a higher instance of lenticular change and cataract formation.

Patient Counseling Information

• Instruct patients to discuss with their physician if they are pregnant or if they might become pregnant (see CONTRAINDICATIONS).
• Instruct patients to discuss with their physician if they have demonstrated a hypersensitivity to mitomycin in the past (see CONTRAINDICATIONS).
• Nursing mothers should be advised that it is not known if Mitosol® is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue use of the drug, taking into account the importance of the drug to the mother. It is recommended that women receiving Mitosol® not breast feed because of the potential for serious adverse reactions in nursing infants (see Use in Specific Populations).
• Patients should be advised of the toxicity of Mitosol® and potential complications.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

Adequate long-term studies in animals to evaluate carcinogenic potential have not been conducted with Mitosol®. Intravenous administration of mitomycin has been found to be carcinogenic in rats and mice. At doses approximating the recommended clinical injectable dose in humans, mitomycin produces a greater than 100 percent increase in tumor incidence in male Sprague-Dawley rats, and a greater than 50 percent increase in tumor incidence in female Swiss mice.

The effect of Mitosol® on fertility is unknown.

Use In Specific Populations

Pregnancy

Teratogenic Effects: Pregnancy Category X (see CONTRAINDICATIONS).

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Mitosol®, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. It is recommended that women receiving Mitosol® not breast feed because of the potential for serious adverse reactions in nursing infants.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

No overall differences in safety and effectiveness have been observed between elderly and younger patients.

Last reviewed on RxList: 2/22/2012
This monograph has been modified to include the generic and brand name in many instances.